Abstract:Abstract Introduction: Peptides containing the asparagine-glycine-arginine (NGR) sequence have been found to specifically bind to cluster of differentiation 13 (CD13) (aminopeptidase N), a tumor neovascular biomarker that is overexpressed on the surface of angiogenic blood vessels and various tumor cells and plays an important role in angiogenesis and tumor progression. The aim of this study was to evaluate the efficacy of a gallium-68 ( 68 Ga)-labeled dimeric cyclic NGR (cNGR) peptide as a new molecular probe that binds to CD13 in vitro and in vivo .Materials and Methods: A dimeric cNGR peptide conjugated with 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA) and DOTA-c(NGR) 2 was synthesized and labeled with 68 Ga. In vitro uptake and binding analysis was performed in two ovarian tumor cell lines, ES2 and SKOV3, each of which have different expression levels of CD13. An in vivo biodistribution study was performed in normal mice, and micro positron emission tomography (PET) imaging was performed in nude mice xenografts with ES2 and SKOV3 tumors. Results : 68 Ga-DOTA-c(NGR) 2 with high radiochemical purity (>95%) was obtained and found to be stable at room temperature and when incubated with bovine serum at 37°C for 3 h. In vitro studies showed that uptake of 68 Ga-DOTA-c(NGR) 2 in ES2 cells increased over time, was higher than that in SKOV3 cells at all time points, and could be blocked by cold DOTA-c(NGR) 2 . Biodistribution studies demonstrated that 68 Ga-DOTA-c(NGR) 2 was mainly excreted from the kidney and rapidly cleared from blood. MicroPET imaging of ES2 tumor xenografts showed that focal uptake in tumors was distinctly observed from 1 to 1.5 h post-injection of 68 Ga-DOTA-c(NGR) 2 . Clear and high-contrast tumor visualization occurred at 1 h, which corresponded to the highest tumor/background ratio of 10.30±0.26. Moreover, accumulation of the probe in ES2 tumors apparently declined with pretreatment of unlabeled peptide, which further proved the specificity of 68 Ga-DOTA-c(NGR) 2 . In SKOV3 tumor models, the tumor was not obviously displayed under the same imaging protocols. Conclusion : We conclude that 68 Ga-DOTA-c(NGR) 2 might be a potential molecular probe for evaluating the expression levels of CD13 in different tumors, thereby providing a basis for targeting angiogenesis in cancer therapy.

Application of a new 68Ga-labeled cNGR dimer peptide to microPET imaging of ovarian cancer